Frontiers in Oncology reviews tumor immunosenescence mechanisms and emerging senotherapeutic strategies in breast cancer

A newly published review synthesizes how age-associated immune decline and cellular senescence drive breast cancer progression, establishing metabolic rescue and targeted senolytics as promising clinical frontiers.

On August 7, 2026, Frontiers in Oncology published a comprehensive review examining the role of tumor immunosenescence in breast cancer progression, therapeutic resistance, and immune evasion.

The authors distinguished T cell senescence (driven by DNA damage response pathways, ATM/ATR, p53/p21, and p16) from T cell exhaustion (TOX-driven and checkpoint-reversible), highlighting that senescent cells remain refractory to conventional PD-1/PD-L1 monotherapy.

The publication summarized the role of senescent cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) in producing SASP components (IL-6, IL-8, TGF-β, and MMPs) that recruit immunosuppressive myeloid-derived suppressor cells (MDSCs) and exclude effector T cells.

The review evaluated emerging senotherapies, including senolytics (navitoclax, venetoclax, dasatinib plus quercetin, and fisetin) to eliminate senescent cells, and senomorphics (ruxolitinib, metformin, and rapamycin) to suppress SASP secretion.

The authors highlighted preclinical findings where metabolic rescue via NAD+ precursor supplementation (e.g., nicotinamide mononucleotide, NMN) restored the cytotoxic function of interferon-stimulated senescent CD8+ T cells and enhanced anti-PD-1 efficacy in triple-negative breast cancer (TNBC) models.

Immunosenescence within the tumor immune microenvironment represents a major obstacle to durable checkpoint inhibitor responses, particularly as breast cancer incidence rises sharply after age 50 and reaches a median age at diagnosis of 62 years.

Therapy-induced senescence (TIS) following genotoxic chemotherapy or radiotherapy acts as a double-edged sword; while it halts tumor proliferation, the persistent SASP from remaining cells can drive relapse, stemness, and metastatic dissemination.

Host-level aging factors, such as thymic involution (which causes a naive T cell output decline of more than 90% by the sixth decade) and myeloid skewing, converge to restrict the T cell receptor (TCR) repertoire and blunt anti-tumor immune responses.

The therapeutic translation of these concepts could expand the addressable market for senotherapeutic developers into oncology, transforming standard-of-care combination regimens.

Metabolic rejuvenation using NAD+ precursors represents a distinct approach from direct senolysis, focusing on restoring the bioenergetic capacity of aged immune cells to enhance existing immunotherapies.

Development of standardized clinical biomarkers, such as p16INK4a expression and single-cell interferon-stimulated gene (ISG) profiling, will be essential to stratify patients and validate on-target senotherapeutic efficacy.

Initiation of clinical trials evaluating combination therapies that sequence senescence-inducing agents (e.g., PARP inhibitors or radiation) with senolytics (like navitoclax or venetoclax) and immune checkpoint blockade.

Translational data clarifying whether NAD+ repletion can safely rescue T-cell function in oncology patients without fueling tumor cell metabolism.